News MediciNova Announces Update On Phase 2b Trial of MN-166 (Ibudilast) Involving 255 Progressive MS Patients MediciNova Announces Update On Phase 2b Trial of MN-166 (Ibudilast) Involving 255 Progressive MS Patients by Patricia Silva, PhD | June 15, 2015 Share this article: Share article via email Copy article link MediciNova, Inc., a biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs, recently announced that the ongoing clinical trial of MN-166 (ibudilast) in patients with progressive multiple sclerosis (progressive MS) has finished the randomization of 255 patients, exceeding the initial goalĀ of 250 patients. The National Institute of Neurological Disorders and Stroke (NINDS) aims to conduct an interim analysis of the drug efficacy in the fall of 2016, once half of the patients have completed the treatment over 96 weeks. Yuichi Iwaki, MD, PhD, President and Chief Executive Officer of MediciNova, Inc., commented in a recent press release, “We are very pleased to have exceeded the enrollment target in this important study.Ā The unmet medical need for progressive MS patients is extremely high as there is no treatment approved for long-term use for these patients.Ā We look forward to providing further updates as the study progresses.” MN-166 is a first-in-class, orally bioavailable, small molecule glial attenuator that suppresses pro-inflammatory cytokines IL-1Ć, TNF-a, and IL-6, and may upregulate the anti-inflammatory cytokine IL-10/ The SPRINT-MS is a Phase 2 Secondary and Primary Progressive Ibudilast NeuroNEXT trial in patients with Multiple Sclerosis designed to evaluate the tolerability, safety, and efficacy of MN-166 (ibudilast) given twice per day to patients with primary or secondary progressive multiple sclerosis (PPMS or SPMS). It involves 28 clinical sites across the United States. Patients were randomized to receive an inactive control (placebo) or MN-166 (ibudilast) 100 mg/day (50 mg twice daily). For the remainder of the study, patients may be either untreated with long-term disease modifying therapy (DMT) or may continue either glatiramer acetate (GA) or interferon beta (IFNĪ²-1a or IFNĪ²-1b) treatment. The trial involves a controlled randomization therapy status (IFN/GA verus. no DMT) and disease status (PPMS versus SPMS). The study primary endpoints are to evaluate the activity of the drug in comparison toĀ the placebo overĀ a period of time of 96 weeks. This will be assessed with magnetic resonance imaging (MRI) using brain parenchymal fraction (BPF). The other primary endpoint involves the assessment of the drug safety and tolerability versus the placebo in with PPMS or SPMS patients. The study secondary endpoints involve imaging analyses of brain and retinal tissue integrity, cortical atrophy disability, cognitive impairment, neuropathic pain and quality-of-life.Ā The study will also include an exploratory analysis of pharmacokinetic and biomarker. Print This Page About the Author Patricia Silva, PhD PatrĆcia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĆcia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles. Tags Ibudilast, MediciNova, MN-166, PPMS, progressive multiple sclerosis, SPMS
April 23, 2024 News by Mary Chapman Itās year 10 for MSAAās upcoming Improving Lives Benefit for MS
April 23, 2024 News by Margarida Maia, PhD AAN 2024: Subcutaneous Ocrevus led to nearly no relapses after year
April 22, 2024 News by Margarida Maia, PhD Viatris launches low-dose Copaxone generic formulation in Canada